Sue Naeyaert, senior director of Biosimilars Policy, EMD Serono, discusses the long-term impact that biosimilars could potentially have on the field of oncology.
Deciding Factors for Front-Line Therapy in Metastatic RCC
April 17th 2024During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on what factors influence physician decision making for frontline therapy in patients with metastatic renal cell carcinoma in the first article of a 2-part series.
Read More